RPID

SEC source: 0001415666-26-000008 · wk-form4_1784932289.xml · derivative · entry 4

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 1,827 shares

Expires 2026-08-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001415666-26-000008 · wk-form4_1784932289.xml · derivative · entry 3

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 1,681 shares

Expires 2026-08-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001415666-26-000008 · wk-form4_1784932289.xml · nonDerivative · entry 2

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,826

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415666-26-000008 · wk-form4_1784932289.xml · nonDerivative · entry 1

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,999

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001853904-26-000020 · wk-form4_1784932183.xml · derivative · entry 2

Spignesi Robert G. Jr. · CIK 0001853904 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 1,402 shares

Expires 2026-08-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001853904-26-000020 · wk-form4_1784932183.xml · nonDerivative · entry 1

Spignesi Robert G. Jr. · CIK 0001853904 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,191,973

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001853904-26-000017 · wk-form4_1780443598.xml · derivative · entry 3

Spignesi Robert G. Jr. · CIK 0001853904 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,787

Underlying: Class A Common Stock · 12,787 shares

Expires 2031-05-29

F1 · kind: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.

F1 · price: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.

F3 · derivative.exercise_date: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 9.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.

SEC source: 0001853904-26-000017 · wk-form4_1780443598.xml · derivative · entry 2

Spignesi Robert G. Jr. · CIK 0001853904 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,787

Underlying: Class A Common Stock · 12,787 shares

Expires 2027-05-29

F1 · kind: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.

F1 · price: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.

F3 · derivative.exercise_date: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 9.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.

SEC source: 0001853904-26-000017 · wk-form4_1780443598.xml · nonDerivative · entry 1

Spignesi Robert G. Jr. · CIK 0001853904 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,190,571

F1 · kind: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.

F2 · balance_after: Includes 7,936 shares acquired under the Rapid Micro Biosystems, Inc. employee stock purchase plan on March 13, 2026.

SEC source: 0001703469-26-000010 · wk-form4_1780443843.xml · derivative · entry 3

PEI MELINDA LITHERLAND · CIK 0001703469 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,787

Underlying: Class A Common Stock · 12,787 shares

Expires 2031-05-29

F1 · kind: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.

F1 · price: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.

F2 · derivative.exercise_date: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.

SEC source: 0001703469-26-000010 · wk-form4_1780443843.xml · derivative · entry 2

PEI MELINDA LITHERLAND · CIK 0001703469 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,787

Underlying: Class A Common Stock · 12,787 shares

Expires 2027-05-29

F1 · kind: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.

F1 · price: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.

F2 · derivative.exercise_date: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.

SEC source: 0001703469-26-000010 · wk-form4_1780443843.xml · nonDerivative · entry 1

PEI MELINDA LITHERLAND · CIK 0001703469 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,687

F1 · kind: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.

SEC source: 0001289733-26-000014 · wk-form4_1780443683.xml · derivative · entry 3

WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,787

Underlying: Class A Common Stock · 12,787 shares

Expires 2031-05-29

F1 · kind: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.

F1 · price: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.

F2 · derivative.exercise_date: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.

SEC source: 0001289733-26-000014 · wk-form4_1780443683.xml · derivative · entry 2

WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,787

Underlying: Class A Common Stock · 12,787 shares

Expires 2027-05-29

F1 · kind: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.

F1 · price: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.

F2 · derivative.exercise_date: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.

SEC source: 0001289733-26-000014 · wk-form4_1780443683.xml · nonDerivative · entry 1

WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 568,981

F1 · kind: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.

SEC source: 0001326794-26-000007 · wk-form4_1780443754.xml · derivative · entry 4

Malloy Kirk · CIK 0001326794 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,787

Underlying: Class A Common Stock · 12,787 shares

Expires 2031-05-29

F1 · kind: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.

F1 · price: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.

F3 · derivative.exercise_date: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.

SEC source: 0001326794-26-000007 · wk-form4_1780443754.xml · derivative · entry 3

Malloy Kirk · CIK 0001326794 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,787

Underlying: Class A Common Stock · 12,787 shares

Expires 2027-05-29

F1 · kind: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.

F1 · price: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.

F3 · derivative.exercise_date: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.

SEC source: 0001326794-26-000007 · wk-form4_1780443754.xml · nonDerivative · entry 1

Malloy Kirk · CIK 0001326794 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,687

F1 · kind: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.

SEC source: 0001900476-26-000008 · wk-form4_1780443944.xml · derivative · entry 3

LOWENSTEIN INESE · CIK 0001900476 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,787

Underlying: Class A Common Stock · 12,787 shares

Expires 2031-05-29

F1 · kind: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.

F1 · price: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.

F2 · derivative.exercise_date: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.

SEC source: 0001900476-26-000008 · wk-form4_1780443944.xml · derivative · entry 2

LOWENSTEIN INESE · CIK 0001900476 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,787

Underlying: Class A Common Stock · 12,787 shares

Expires 2027-05-29

F1 · kind: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.

F1 · price: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.

F2 · derivative.exercise_date: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.

SEC source: 0001900476-26-000008 · wk-form4_1780443944.xml · nonDerivative · entry 1

LOWENSTEIN INESE · CIK 0001900476 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,687

F1 · kind: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.

SEC source: 0002070373-26-000003 · wk-form4_1779837876.xml · derivative · entry 2

Bika Dafni · CIK 0002070373 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,700

Underlying: Class A Common Stock · 38,700 shares

Expires 2036-05-20

F2 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.

SEC source: 0002070373-26-000003 · wk-form4_1779837876.xml · nonDerivative · entry 1

Bika Dafni · CIK 0002070373 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,300

F1 · shares: Grant of restricted stock units ("RSUs") that vests in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.

SEC source: 0001703469-26-000007 · wk-form4_1779837928.xml · derivative · entry 2

PEI MELINDA LITHERLAND · CIK 0001703469 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,700

Underlying: Class A Common Stock · 38,700 shares

Expires 2036-05-20

F2 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.

SEC source: 0001703469-26-000007 · wk-form4_1779837928.xml · nonDerivative · entry 1

PEI MELINDA LITHERLAND · CIK 0001703469 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,900

F1 · shares: Grant of restricted stock units ("RSUs") that vests in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.

SEC source: 0001415666-26-000005 · wk-form4_1779837903.xml · derivative · entry 2

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,700

Underlying: Class A Common Stock · 38,700 shares

Expires 2036-05-20

F2 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.

SEC source: 0001415666-26-000005 · wk-form4_1779837903.xml · nonDerivative · entry 1

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,318

F1 · shares: Grant of restricted stock units ("RSUs") that vests in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.

SEC source: 0001326794-26-000003 · wk-form4_1779838019.xml · derivative · entry 3

Malloy Kirk · CIK 0001326794 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,700

Underlying: Class A Common Stock · 38,700 shares

Expires 2036-05-20

F3 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.

SEC source: 0001326794-26-000003 · wk-form4_1779838019.xml · nonDerivative · entry 1

Malloy Kirk · CIK 0001326794 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,900

F1 · shares: Grant of restricted stock units ("RSUs") that vests in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.

SEC source: 0001900476-26-000005 · wk-form4_1779837958.xml · derivative · entry 2

LOWENSTEIN INESE · CIK 0001900476 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,700

Underlying: Class A Common Stock · 38,700 shares

Expires 2036-05-20

F2 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.

SEC source: 0001900476-26-000005 · wk-form4_1779837958.xml · nonDerivative · entry 1

LOWENSTEIN INESE · CIK 0001900476 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,900

F1 · shares: Grant of restricted stock units ("RSUs") that vests in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.

SEC source: 0001193125-26-237016 · ownership.xml · derivative · entry 4

Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner

Bain Capital Life Sciences Partners, LP · CIK 0001703030 · 10% owner

Bain Capital Life Sciences Fund, L.P. · CIK 0001687968 · 10% owner

BCIP Life Sciences Associates, LP · CIK 0001702921 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 1,463,000

Underlying: Class A Common Stock · 1,463,000 shares

Expires 2031-05-20

F1 · kind: On May 20, 2026, BCLS I Investco, LP ("BCLS I Investco") purchased, in an underwritten public offering, a Pre-Funded Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each pre-funded warrant and accompanying Series A Warrant and Series B Warrant was $1.945.

F1 · price: On May 20, 2026, BCLS I Investco, LP ("BCLS I Investco") purchased, in an underwritten public offering, a Pre-Funded Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each pre-funded warrant and accompanying Series A Warrant and Series B Warrant was $1.945.

F2 · derivative.exercise_date: The Pre-Funded Warrant, Series A Warrant and Series B Warrant cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 9.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.

F2 · derivative.underlying_shares: The Pre-Funded Warrant, Series A Warrant and Series B Warrant cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 9.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.

F1 · ownership.nature: On May 20, 2026, BCLS I Investco, LP ("BCLS I Investco") purchased, in an underwritten public offering, a Pre-Funded Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each pre-funded warrant and accompanying Series A Warrant and Series B Warrant was $1.945.

F6 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the general partner of each of BCLSP and BCLS I Investco and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

SEC source: 0001193125-26-237016 · ownership.xml · derivative · entry 3

Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner

Bain Capital Life Sciences Partners, LP · CIK 0001703030 · 10% owner

Bain Capital Life Sciences Fund, L.P. · CIK 0001687968 · 10% owner

BCIP Life Sciences Associates, LP · CIK 0001702921 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 1,463,000

Underlying: Class A Common Stock · 1,463,000 shares

Expires 2027-05-20

F1 · kind: On May 20, 2026, BCLS I Investco, LP ("BCLS I Investco") purchased, in an underwritten public offering, a Pre-Funded Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each pre-funded warrant and accompanying Series A Warrant and Series B Warrant was $1.945.

F1 · price: On May 20, 2026, BCLS I Investco, LP ("BCLS I Investco") purchased, in an underwritten public offering, a Pre-Funded Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each pre-funded warrant and accompanying Series A Warrant and Series B Warrant was $1.945.

F2 · derivative.exercise_date: The Pre-Funded Warrant, Series A Warrant and Series B Warrant cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 9.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.

F2 · derivative.underlying_shares: The Pre-Funded Warrant, Series A Warrant and Series B Warrant cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 9.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.

F1 · ownership.nature: On May 20, 2026, BCLS I Investco, LP ("BCLS I Investco") purchased, in an underwritten public offering, a Pre-Funded Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each pre-funded warrant and accompanying Series A Warrant and Series B Warrant was $1.945.

F6 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the general partner of each of BCLSP and BCLS I Investco and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

SEC source: 0001193125-26-237016 · ownership.xml · derivative · entry 2

Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner

Bain Capital Life Sciences Partners, LP · CIK 0001703030 · 10% owner

Bain Capital Life Sciences Fund, L.P. · CIK 0001687968 · 10% owner

BCIP Life Sciences Associates, LP · CIK 0001702921 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 1,463,000

Underlying: Class A Common Stock · 1,463,000 shares

Expires not disclosed

F1 · kind: On May 20, 2026, BCLS I Investco, LP ("BCLS I Investco") purchased, in an underwritten public offering, a Pre-Funded Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each pre-funded warrant and accompanying Series A Warrant and Series B Warrant was $1.945.

F1 · price: On May 20, 2026, BCLS I Investco, LP ("BCLS I Investco") purchased, in an underwritten public offering, a Pre-Funded Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each pre-funded warrant and accompanying Series A Warrant and Series B Warrant was $1.945.

F2 · derivative.exercise_date: The Pre-Funded Warrant, Series A Warrant and Series B Warrant cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 9.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.

F3 · derivative.expiration_date: The Pre-Funded Warrant does not expire.

F2 · derivative.underlying_shares: The Pre-Funded Warrant, Series A Warrant and Series B Warrant cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 9.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.

F1 · ownership.nature: On May 20, 2026, BCLS I Investco, LP ("BCLS I Investco") purchased, in an underwritten public offering, a Pre-Funded Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 1,463,000 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each pre-funded warrant and accompanying Series A Warrant and Series B Warrant was $1.945.

F6 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the general partner of each of BCLSP and BCLS I Investco and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

SEC source: 0001872301-26-000012 · wk-form4_1773359600.xml · nonDerivative · entry 1

Wilson John J. Addington · CIK 0001872301 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 316,762

F1 · shares: Represents the automatic sale of stock to cover the associated tax obligations with the vesting of restricted stock units.

SEC source: 0001289733-26-000011 · wk-form4_1773359572.xml · nonDerivative · entry 1

WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 556,194

F1 · shares: Represents the automatic sale of stock to cover the associated tax obligations with the vesting of restricted stock units.

SEC source: 0001853904-26-000013 · wk-form4_1773359540.xml · nonDerivative · entry 1

Spignesi Robert G. Jr. · CIK 0001853904 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,169,848

F1 · shares: Represents the automatic sale of stock to cover the associated tax obligations with the vesting of restricted stock units.

SEC source: 0001107158-26-000002 · wk-form4_1772493071.xml · derivative · entry 2

RICCIARDI NATALE S · CIK 0001107158 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 842 shares

Expires 2026-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001107158-26-000002 · wk-form4_1772493071.xml · nonDerivative · entry 1

RICCIARDI NATALE S · CIK 0001107158 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,442

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001872301-26-000009 · wk-form4_1771633232.xml · nonDerivative · entry 1

Wilson John J. Addington · CIK 0001872301 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 326,365

F1 · shares: Represents the automatic sale of stock to cover the associated tax obligations with the vesting of restricted stock units.

SEC source: 0001289733-26-000008 · wk-form4_1771633140.xml · nonDerivative · entry 1

WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 563,674

F1 · shares: Represents the automatic sale of stock to cover the associated tax obligations with the vesting of restricted stock units.

SEC source: 0001853904-26-000010 · wk-form4_1771633029.xml · nonDerivative · entry 1

Spignesi Robert G. Jr. · CIK 0001853904 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,187,770

F1 · shares: Represents the automatic sale of stock to cover the associated tax obligations with the vesting of restricted stock units.

SEC source: 0001380106-26-000017 · wk-form4_1771029325.xml · derivative · entry 2

Wilson John J. Addington · CIK 0001872301 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 147,000

Underlying: Class A Common Stock · 147,000 shares

Expires 2036-02-10

F2 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 11, 2026.

SEC source: 0001380106-26-000017 · wk-form4_1771029325.xml · nonDerivative · entry 1

Wilson John J. Addington · CIK 0001872301 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 331,768

F1 · shares: Grant of restricted stock units ("RSUs") that vest in three annual installments with 33.4% vesting on the first anniversary of February 11, 2026 (the "grant date") and 33.3% vesting on each of the second and third anniversaries of the grant date provided that the Reporting Person remains in continuous service on each vesting date.

SEC source: 0001380106-26-000013 · wk-form4_1771029199.xml · derivative · entry 2

Spignesi Robert G. Jr. · CIK 0001853904 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 528,000

Underlying: Class A Common Stock · 528,000 shares

Expires 2036-02-10

F2 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 11, 2026.

SEC source: 0001380106-26-000013 · wk-form4_1771029199.xml · nonDerivative · entry 1

Spignesi Robert G. Jr. · CIK 0001853904 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,226,097

F1 · shares: Grant of restricted stock units ("RSUs") that vest in three annual installments with 33.4% vesting on the first anniversary of February 11, 2026 (the "grant date") and 33.3% vesting on each of the second and third anniversaries of the grant date provided that the Reporting Person remains in continuous service on each vesting date.

SEC source: 0001380106-26-000015 · wk-form4_1771029276.xml · derivative · entry 2

WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 193,000

Underlying: Class A Common Stock · 193,000 shares

Expires 2036-02-10

F2 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 11, 2026.

SEC source: 0001380106-26-000015 · wk-form4_1771029276.xml · nonDerivative · entry 1

WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 580,928

F1 · shares: Grant of restricted stock units ("RSUs") that vest in three annual installments with 33.4% vesting on the first anniversary of February 11, 2026 (the "grant date") and 33.3% vesting on each of the second and third anniversaries of the grant date provided that the Reporting Person remains in continuous service on each vesting date.

SEC source: 0001872301-26-000005 · wk-form4_1770767900.xml · nonDerivative · entry 1

Wilson John J. Addington · CIK 0001872301 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 257,768

F1 · shares: Represents the automatic sale of stock to cover the associated tax obligations with the vesting of restricted stock units.

F2 · balance_after: Includes 29,904 shares acquired under the Rapid Micro Biosystems, Inc. employee stock purchase plan on March 14, 2025.

SEC source: 0001853904-26-000004 · wk-form4_1770767569.xml · nonDerivative · entry 1

Spignesi Robert G. Jr. · CIK 0001853904 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 962,097

F1 · shares: Represents the automatic sale of stock to cover the associated tax obligations with the vesting of restricted stock units.